JD-SW
09618
MEITUAN-W
03690
JD HEALTH
06618
BABA-W
09988
TME-SW
01698
(Q6)Jun 30, 2024 | (FY)Dec 31, 2023 | (Q6)Jun 30, 2023 | (FY)Dec 31, 2022 | (Q6)Jun 30, 2022 | (FY)Dec 31, 2021 | (Q6)Jun 30, 2021 | (FY)Dec 31, 2020 | (Q6)Jun 30, 2020 | (FY)Dec 31, 2019 | |
---|---|---|---|---|---|---|---|---|---|---|
Turnover | -0.27%1.16B | -20.69%2.39B | -26.02%1.16B | -15.29%3.01B | -2.15%1.57B | 42.72%3.56B | 63.80%1.61B | 5.32%2.49B | -17.36%982.52M | -16.88%2.37B |
Operating income | -0.27%1.16B | -20.69%2.39B | -26.02%1.16B | -15.29%3.01B | -2.15%1.57B | 42.72%3.56B | 63.80%1.61B | 5.32%2.49B | -17.36%982.52M | -16.88%2.37B |
Cost of sales | 3.39%-998.23M | 20.65%-2.12B | 23.61%-1.03B | 7.25%-2.67B | -3.55%-1.35B | -37.05%-2.88B | -55.05%-1.31B | -9.58%-2.1B | 10.47%-842.42M | 17.96%-1.92B |
Operating expenses | 3.39%-998.23M | 20.65%-2.12B | 23.61%-1.03B | 7.25%-2.67B | -3.55%-1.35B | -37.05%-2.88B | -55.05%-1.31B | -9.58%-2.1B | 10.47%-842.42M | 17.96%-1.92B |
Gross profit | 24.21%163.6M | -20.99%270M | -40.72%131.71M | -49.52%341.73M | -26.72%222.19M | 73.20%676.97M | 116.41%303.19M | -12.91%390.87M | -43.50%140.1M | -11.95%448.81M |
Selling expenses | -6.90%-46.8M | 6.26%-86.33M | 19.78%-43.78M | 6.56%-92.1M | -0.93%-54.57M | -35.67%-98.57M | -66.55%-54.07M | 0.47%-72.65M | 9.37%-32.47M | 1.98%-72.99M |
Administrative expenses | 1.64%-66.39M | -5.57%-138.97M | 6.83%-67.5M | 22.48%-131.64M | 20.72%-72.45M | -20.16%-169.82M | -52.27%-91.39M | -2.52%-141.33M | 12.43%-60.02M | 4.04%-137.86M |
Research and development expenses | -2.30%-40.2M | 22.47%-90.24M | 23.94%-39.29M | 11.23%-116.39M | 7.41%-51.66M | -65.04%-131.12M | -85.17%-55.8M | 6.50%-79.45M | 32.02%-30.13M | 10.78%-84.97M |
Impairment and provision | 92.80%-101K | -80.48%419K | -215.30%-1.4M | 266.61%2.15M | 806.98%1.22M | 74.52%-1.29M | ---172K | -12,537.50%-5.06M | ---- | 88.57%-40K |
-Other impairment is provision | 92.80%-101K | -80.48%419K | -215.30%-1.4M | 266.61%2.15M | 806.98%1.22M | 74.52%-1.29M | ---172K | -12,537.50%-5.06M | ---- | 88.57%-40K |
Special items of operating profit | 21.84%32.27M | -39.81%79.88M | -45.95%26.48M | 453.71%132.72M | 533.61%49M | 8.16%23.97M | -42.30%7.73M | 83.69%22.16M | 343.51%13.4M | 179.00%12.06M |
Operating profit | 581.90%42.37M | -74.53%34.76M | -93.37%6.21M | -54.53%136.47M | -14.41%93.72M | 162.03%300.15M | 254.53%109.5M | -30.58%114.55M | -69.81%30.89M | -17.62%165.02M |
Financing cost | 11.36%-23.14M | 12.02%-52.43M | 9.16%-26.1M | 5.14%-59.6M | 6.15%-28.73M | -26.64%-62.83M | -50.77%-30.62M | -8.25%-49.62M | 2.49%-20.31M | 0.99%-45.84M |
Earning before tax | 196.74%19.24M | -123.00%-17.68M | -130.60%-19.89M | -67.61%76.87M | -17.62%64.98M | 265.49%237.32M | 645.70%78.88M | -45.52%64.93M | -87.02%10.58M | -22.62%119.18M |
Tax | -293.41%-851K | 110.12%836K | 104.77%440K | 71.54%-8.26M | 17.99%-9.23M | -1,124.72%-29.04M | -268.12%-11.26M | 86.94%-2.37M | 81.79%-3.06M | 22.10%-18.15M |
After-tax profit from continuing operations | 194.55%18.39M | -124.55%-16.84M | -134.88%-19.45M | -67.06%68.6M | -17.55%55.75M | 232.93%208.28M | 799.24%67.62M | -38.08%62.56M | -88.37%7.52M | -22.71%101.03M |
Earning after tax | 194.55%18.39M | -124.55%-16.84M | -134.88%-19.45M | -67.06%68.6M | -17.55%55.75M | 232.93%208.28M | 799.24%67.62M | -38.08%62.56M | -88.37%7.52M | -22.71%101.03M |
Minority profit | 187.00%3.36M | -96.68%711K | -127.97%-3.86M | -54.81%21.44M | -13.62%13.81M | 509.10%47.44M | 1,407.44%15.99M | -58.67%7.79M | -109.20%-1.22M | -11.76%18.84M |
Profit attributable to shareholders | 196.43%15.03M | -137.21%-17.55M | -137.16%-15.58M | -70.67%47.17M | -18.77%41.94M | 193.66%160.84M | 490.56%51.63M | -33.35%54.77M | -82.98%8.74M | -24.85%82.18M |
Basic earnings per share | 200.00%0.03 | -144.44%-0.04 | -137.50%-0.03 | -71.88%0.09 | -20.00%0.08 | 190.91%0.32 | 400.00%0.1 | -31.25%0.11 | -80.00%0.02 | -27.27%0.16 |
Diluted earnings per share | ||||||||||
Currency Unit | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY |
Accounting Standards | HKAS | HKAS | HKAS | HKAS | HKAS | HKAS | HKAS | HKAS | HKAS | HKAS |
Audit Opinions | -- | Unqualified Opinion | -- | Unqualified Opinion | -- | Unqualified Opinion | -- | Unqualified Opinion | -- | Unqualified Opinion |
Auditor | -- | Deloitte Guan Huang Chen Fang Certified Public Accountants | -- | Deloitte Guan Huang Chen Fang Certified Public Accountants | -- | Deloitte Guan Huang Chen Fang Certified Public Accountants | -- | Deloitte Guan Huang Chen Fang Certified Public Accountants | -- | Deloitte Guan Huang Chen Fang Certified Public Accountants |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.
Unlock the Full List